Plasma D-dimer in evaluation of clinical efficacy of TACE for treatment of primary hepatic carcinoma
10.13929/j.1672-8475.201709005
- VernacularTitle:血浆D-二聚体评估TACE治疗原发性肝癌的疗效
- Author:
Ying CHEN
1
Author Information
1. 葫芦岛市中心医院介入血管外科
- Keywords:
Liver neoplasms;
Chemoembolization,therapeutic;
D-dimer;
Prognosis
- From:
Chinese Journal of Interventional Imaging and Therapy
2018;15(5):264-267
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of plasma D-dimer in evaluating therapeutic effect of TACE for primary hepatic carcinoma (PHC).Methods Data of 86 PHC patients treated with TACE were selected,and the plasma D-dimer levels before TACE within a week (D0),1 month after TACE (D1) and during disease processing (D2) were measured.One month after intervention,the patients were divided into disease control group and progressive disease group according to modified response evaluation criteria in solid tumors,and the progression-free survival (PFS) was recorded.The plasma D-dimer levels were compared at D0 and D1 between two groups,and the correlation of D-dimer levels at D0,D1,D2 with PFS was analyzed respectively.The relation of plasma D-dimer levels and PFS was evaluated.Results There was no statistical difference of plasma D-dimer levels between D0 and D1 in disease control group (both P>0.05),but plasma D-dimer levels at D1 were higher than those at D0 in progressive disease group (P=0.000 1).At D0 and D1,D-dimer levels in progressive disease group were higher than those in disease control group (both P<0.05).D-dimer levels at D0,D1 and D2 were negatively correlated with PFS (rs =-0.267,-0.454,-0.368,all P<0.05).Compared with positive D-dimer levels,patients with negative D-dimer levels at D1,D2 possessed longer PFS (both P<0.05).Conclusion The level of plasma D-dimer can serve as a biomarker to evaluate PHC patients' state,therapeutic effect of TACE and prognosis.High D-dimer is a risk factor for PHC patients.